Put companies on watchlist
BB BIOTECH AG
ISIN: CH0038389992
WKN: A0NFN3
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

BB BIOTECH AG · ISIN: CH0038389992 · EQS - adhoc news (64 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1539437
20 January 2023 07:00AM

BB Biotech AG closes the 2022 fiscal year with a loss


EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Annual Results
BB Biotech AG closes the 2022 fiscal year with a loss

20-Jan-2023 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

January 20, 2023

BB Biotech AG closes the 2022 fiscal year with a loss

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its financial year 2022.

Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a loss of approximately CHF 358 mn for the financial year 2022 (loss of CHF 405 mn in the previous year). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The publication of all relevant portfolio data will take place on January 20, 2023 at 7:00 am and the complete annual report will be published on February 17, 2023.

 

For further information:

Media Relations
Bellevue Asset Management AG
Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

 

Company profile 
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.


20-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 1539437

 
End of Announcement EQS News Service

1539437  20-Jan-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1539437&application_name=news&site_id=boersengefluester
Visual performance / price development - BB BIOTECH AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.